STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe - European Commission approves STADA’s Kefdensis® and Zvogra® denosumab biosimilars for all indications of reference medicines Prolia® and ...
Capital Markets Day 2025: Focus on defense business – RENK Group AG targets consolidated revenue of €2.8 billion to €3.2 billion by 2030 - Development of new product segments, M&A activities, and increased localization are central pillars - ...
9M 2025 results: RENK Group AG continues consistent growth - Consolidated revenue rises to €928 million (+19.2%) - Increase in adjusted EBIT to €141 million (+25.5%) - Total order backlog sets new record at €6.4 billion - Defense business strongest growth driver - Management Board confirms its forecast for full-year 2025 Augsburg, November 13, 2025 - ...
DHL Group setzt Ergebniswachstum im dritten Quartal fort - Konzernumsatz sinkt aufgrund von Währungseffekten im dritten Quartal auf 20,1 Milliarden Euro (Q3 2024: 20,6 Milliarden Euro) - Höhere Profitabilität: EBIT legt auf 1,5 Milliarden Euro zu ...
RENK supplies additional transmissions for K2 in Poland and concludes service support agreement with Ukraine - New orders substantiate key role as supplier of battle-tested propulsion solutions - Commitment underscores regard for Poland as ...
